4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO David Kirn Sells 12,930 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO David Kirn sold 12,930 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total transaction of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

4D Molecular Therapeutics Trading Down 4.5 %

NASDAQ FDMT traded down $0.99 during trading hours on Wednesday, hitting $21.01. The company’s stock had a trading volume of 832,424 shares, compared to its average volume of 863,338. The stock has a fifty day moving average of $24.67 and a 200 day moving average of $24.67. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.07. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%. On average, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on FDMT. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, June 7th. BMO Capital Markets decreased their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st. Jefferies Financial Group increased their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, Barclays began coverage on shares of 4D Molecular Therapeutics in a research note on Monday, April 15th. They set an “overweight” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $45.63.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently bought and sold shares of FDMT. Redmile Group LLC acquired a new stake in 4D Molecular Therapeutics in the first quarter worth $40,189,000. RA Capital Management L.P. raised its holdings in 4D Molecular Therapeutics by 35.6% in the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after purchasing an additional 1,093,680 shares during the period. Goldman Sachs Group Inc. raised its holdings in 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock worth $16,539,000 after purchasing an additional 658,069 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in 4D Molecular Therapeutics by 1,076.1% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 641,000 shares of the company’s stock worth $20,422,000 after purchasing an additional 586,500 shares during the period. Finally, Vanguard Group Inc. raised its holdings in 4D Molecular Therapeutics by 25.3% in the first quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock worth $74,551,000 after purchasing an additional 473,094 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.